[PRESS RELEASE] – SMITHS FALLS, Ontario, Sept. 8, 2026 – Canopy Growth Corp., a leading global company committed to bettering lives through cannabis, announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats and new formulations within its existing oil and softgel ranges.
“Expanding our product offering in established markets like Australia is central to our international medical strategy,” Canopy Growth CEO Luc Mongeau said. “These new formats and formulations reflect the continued strength of our global supply chain and our ability to evolve our existing portfolio while bringing a broader range of high-quality products to international markets.”
New Formats Now Available
- Pastilles – Canopy Growth’s first pastille format in Australia:
- Tweed Red 10
- Tweed Blue 10:10
- Spectrum Triple Balance 10:10:10
- Spectrum Dawn 1:10:5
- All-in-one vapes – Canopy Growth’s first AIO vape format in Australia:
- 7 ACRES Fondant Live Resin AIO Vape 1 mL (Indica)
- Spectrum Therapeutics Reserve Berea Live Resin AIO Vape 1 mL (Sativa)
Expanded Formulations Now Available
- Oils – Canopy Growth’s first Australian oils to include CBG and CBN:
- Spectrum Flow
- Spectrum Sunset
- Softgels – expanding the range beyond isolate based formulations:
- Spectrum White 50
- Spectrum Black 10
Also New to the Portfolio
- Flower:
- Two new SKUs added under the Twd. value range
“Prescribers and patients in Australia are asking for more choice in format and formulation,” said Andrew Bevan, president of medical at Canopy Growth. “These launches give clinicians more options to tailor treatment approaches, while our new pastille and oil offerings reflect formulation work shaped by insights from our Canadian clinic and provider network.”
